What we know or can deduce about NOXCOVID:
- Noxopharm must have evidence that Veyonda can stop a cytokine storm. Why would a small company spend millions of dollars on a trial, unless it had reason to believe its drug might be effective?
- Dr Gartier of the Hudson Institute is a leader in STING and Septic Shock research. Dr Gartier discovered that Veyonda inhibits STING when it is acting abnormally, which then inhibits a wide range of cytokines associated with death and disability in COVID-19 patients
- Inhibition of IL-6 alone does not work. Sanofi recently announced that IL-6 inhibitor Kevzara failed its Phase III trial against severely or critically-ill COVID 19 patients. See https://tinyurl.com/y3kdl7b5
- The primary endpoint was time to improvement of 2 points or greater on a 7-point clinical scale (where 1=death; 2=hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation;3=hospitalized, on non-invasive ventilation or high flow oxygen devices; 4=hospitalized, requiring supplemental oxygen; 5=hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6=hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7=not hospitalized). The key secondary endpoint was percentage of patients alive at Day 29.
- NOXCOVID seeks to help patients before they suffer lethal organ damage. Sanofi appears to have recruited category 2 patients – hospitalized, on invasive mechanical ventilation; whereas Noxopharm looks like it will recruit category 4 patients – hospitalized, requiring supplementary oxygen. The object is to stop the cytokine storm before mechanical ventilation is required.
- Efficacy should be known in a relatively short period. Treatment lasts 14 days, with an option to extend to 28 days. It will not take treating physicians long to know whether patients have regressed to category 3 (need high-flow oxygen); or improved to category 5 (not requiring oxygen).
- Trial Implications. If treatment is effective, the world will be a safer place. The big payoff to Noxopharm, however, is that Veyonda should become the approved drug for Septic Shock – an ongoing problem that kills about 10 million people each year.
- Forums
- ASX - By Stock
- NOX
- NOXCOVID
NOX
noxopharm limited
Add to My Watchlist
1.47%
!
6.7¢

NOXCOVID
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.7¢ |
Change
-0.001(1.47%) |
Mkt cap ! $19.87M |
Open | High | Low | Value | Volume |
6.7¢ | 6.8¢ | 6.7¢ | $2.215K | 33.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 64402 | 6.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 52835 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 64402 | 0.067 |
1 | 59378 | 0.066 |
1 | 10000 | 0.062 |
1 | 16393 | 0.061 |
1 | 20000 | 0.059 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 52835 | 2 |
0.069 | 90409 | 1 |
0.070 | 261666 | 1 |
0.072 | 43942 | 1 |
0.080 | 100000 | 1 |
Last trade - 11.00am 21/07/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |